Show simple item record

dc.contributor.authorImholz, Ben
dc.contributor.authorHeijster, Jack
dc.contributor.authorTahrani, Abd
dc.contributor.authorKooy, Adriaan
dc.date.accessioned2023-07-05T12:47:00Z
dc.date.available2023-07-05T12:47:00Z
dc.date.issued2023-05-11
dc.identifier.citationImholz B, Heijster J, Tahrani A, Kooy A. Treatment of Painful Diabetic Neuropathy Using Frequency Rhythmic Electro Magnetic Neural Stimulation (FREMS); Effectiveness in Daily Practice. Diabetes Metab Syndr Obes. 2023 May 11;16:1383-1391. doi: 10.2147/DMSO.S401727.en_US
dc.identifier.issn1178-7007
dc.identifier.doi10.2147/DMSO.S401727
dc.identifier.pmid37197061
dc.identifier.urihttp://hdl.handle.net/20.500.14200/1172
dc.description.abstractBackground: Painful diabetic peripheral neuropathy (PDPN) is common and difficult to treat with limited treatment options. We assessed the efficacy of frequency rhythmic electromagnetic neural stimulation (FREMS) in patients with PDPN. Methods: An uncontrolled prospective survey of patients with PDPN and pain despite at least two lines of pharmacotherapy. The primary outcome, 50% reduction in pain scores at 1 and/or 3 months post FREMS. FREMS was applied to both legs below the knees using 4 sets of electrodes per leg; the treatment consisted of 10 sessions of 35 min applications given over 14 days. FREMS was repeated every 4 months and patients were followed up for 12 months. Pain was assessed using the neuropathic pain symptom inventory (NPSI) and quality of life (QOL) by the EQ-5D. Results: Out of 336 subjects, 248 patients met the inclusion criteria (56% men), average age and diabetes duration were 65 and 12.6 years respectively. FREMS was associated with a median decrease NPSI of 31% at M1 (range -100;+93%), and a median decrease of -37.5% at M3 (range -100;+250%). The 50% reduction in pain was reached in 80/248 (32.3%) and 87/248 (35.1%) after M1 and M3 respectively. The change in NPSI was accompanied by a decrease in self reported use of opiates of >50%. Conclusion: FREMS treatment was associated with a significant reduction in pain severity over a three months period in patients who did not have adequate response to pharmacotherapy. Randomised (sham)-controlled trials examining the role of FREMS as a treatment for PDPN in non-responders to pharmacotherapy are needed.en_US
dc.language.isoenen_US
dc.publisherTaylor and Francis Groupen_US
dc.relation.urlhttp://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journalen_US
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/journals/1441/en_US
dc.rights© 2023 Imholz et al.
dc.subjectEndocrinologyen_US
dc.subjectDiseases & disorders of systemic, metabolic or environmental originen_US
dc.subjectPractice of medicineen_US
dc.titleTreatment of painful diabetic neuropathy using Frequency Rhythmic Electro Magnetic Neural Stimulation (FREMS); effectiveness in daily practice.en_US
dc.typeArticle
dc.source.journaltitleDiabetes, Metabolic Syndrome and Obesity
dc.source.volume16
dc.source.beginpage1383
dc.source.endpage1391
dc.source.countryNew Zealand
rioxxterms.versionNAen_US
oa.grant.openaccessnaen_US


This item appears in the following Collection(s)

Show simple item record